Basic Information
| LncRNA/CircRNA Name | MGC45800 |
| Synonyms | NA |
| Region | GRCh38_4:182138658-182144515 |
| Ensemble | NA |
| Refseq | NR_027107 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | RNA-seq, Microarray, RIP, qPCR |
| Sample | cell lines (A549,NCI-H1299) |
| Expression Pattern | up-regulated |
| Function Description | EPEL,known as LOC90768 and MGC45800, was associated with the relapse and survival of lung cancer patients and promoted lung cancer cell proliferation through the activation of E2F target genes. EPEL knockdown specifically down-regulated the expression of cell cyclerelated E2F target genes, including Cyclin B1 (CCNB1), in lung cancer cells but not that of apoptosis- or metabolism-related E2F target genes. EPEL interacted with E2F1 and regulated the expression of the E2F target genes by changing the binding efficiency of E2F1 to the E2F target promoters. Moreover, the expression levels of EPEL and CCNB1 both alone and in combination were robust prognostic markers for lung cancer. |
| Pubmed ID | 29448242 |
| Year | 2018 |
| Title | The LncRNA EPEL Promotes Lung Cancer Cell Proliferation Through E2F Target Activation |
External Links
| Links for MGC45800 | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |